Neuromagen Pharma is a pharmaceutical company developing a new class of innovative small molecules which activate Telomerase Reverse Transcriptase (TERT) – an enzyme which plays a major role in preventing cellular senescence.
Our goal is to develop drugs which will delay the onset, and the progression of neurodegenerative diseases and specifically of ALS and improve and extend patients’ lives
Telomerase is a key enzyme for cell lifespan and survival that prevents telomere shortening and the subsequent cellular senescence that is observed after many rounds of cell division.
In addition to its role in telomer re-elongation which increases the cell lifespan, Telomerase catalytic protein component, Telomerase Reverse Transcriptase (TERT), possesses non-canonical functions that enhances the ability of cells and tissues to cope with various cellular damages including oxidative stress.
The neuroprotective effects of telomerase reverse transcriptase (TERT) in the brain and spinal cord were previously demonstrated by us and by others.
We are developing a family of synthetic small molecules (AGS) which activate TERT transcription. Our compounds demonstrated remarkable therapeutic results in various murine models of neurodegenerative diseases, in a dose and time-dependent manner.
In the hSOD1 Tg
murine models of ALS, treatment with AGS-499 delayed the onset and progression of the disease, increased the survival of motor neurons in the mice spinal cord, and increased survival of the mice
When tested on primary murine hippocampal neurons which were subjected to amyloid beta toxicity, treatment with AGS resulted in increased neuronal survival
In-vitro testing of AGS
effects on human mesenchymal stem cells derived from ALS and MS patients demonstrated increased survival and ameliorated oxidative
stress
In the 5XFAD murine
model of Alzheimer
Disease, AGS treatment reduced amyloid beta
plaque burden and
improved cognitive
behavior
Founder, CEO & CSO
Chief Operating Officer
Senior Clinical and Regulatory Advisor
Eitan E, Tichon A, Gazit A, Gitler D, Slavin S, Priel E.
EMBO Mol Med. 2012 Apr;4(4):313-29. doi: 10.1002/emmm.201200212. Epub 2012 Feb 20.
Tichon A, Eitan E, Kurkalli BG, Braiman A, Gazit A, Slavin S, Beith-Yannai E, Priel E.
Curr Mol Med. 2013 Jul;13(6):1010-22. doi: 10.2174/1566524011313060013.
Baruch-Eliyahu N, Rud V, Braiman A, Priel E.
Sci Rep. 2019 Dec 2;9(1):18118. doi: 10.1038/s41598-019-54741-7.
23/06/2022
11/05/2022
05/05/2022
21/03/2022
09/02/2022
18/10/2021
10/10/2021
01/10/2021
Beer Sheva High Tech Park, 77 HaEnergya St.
P. O. Box 5316, Beer Sheva, Israel
© 2021 Neuromagen Pharma
Design & Development imarkimage
HaEnergia 77, Beer Sheva
Founder, CEO & CSO
Esther is a professor of Molecular Biology and the Head of the Laboratory for Nucleic Acids Topology, at the Faculty of Health Sciences, Ben Gurion University of the Negev. Esther and her research group focus is on the involvement of topoisomerases and telomerase in neurodegenerative diseases, cardiovascular disfunction and diabetes. With more than 40 years of research, Esther and her research group published close to 100 scientific publications, and she is the inventor of more than 80 patents. Esther is considered a world expert in the field of neuroprotection by telomerase.
Esther received her M.Sc. in Human Genetics from Tel Aviv University, and her D.Sc. from the Technion Institute of Technology. She received several academic awards among them the Fulbright scholar award as a visiting scientist in the National Institute of Health in the USA.
Chief Operating Officer
Daniella is a Chemical Engineer and our Chief Operating Officer. Prior to joining Neuromagen Daniella served as an Executive Office Manager at Be’er Sheva based real-estate and law firm, and as an instructor of Chemistry, physics, and mathematics for undergraduate level students. Daniella completed her B.Sc. in Chemical Engineering at the Ben-Gurion University and is a graduate of Ben-Gurion’s Women Entrepreneurs and Oazis Accelerator Programs.
Helena is a life-science executive with over 15 years of experience in leading roles at pharmaceuticals and medical devices companies. Helena has an extensive background in drug development, clinical development, and regulation, with a proven track record of leading the product development process from concept to clinical studies worldwide, and successful regulatory submissions in Europe and in the USA. Helena is the founder and CEO of Titania Technologies, a Netherlands-based strategic consultancy firm. She serves as an advisor and mentor for life-sciences and healthcare entrepreneurs and start-up's. Helena earned her Ph.D. in molecular medicine and human genetics from Tel Aviv University and her MBA from the Richman University (IDC) Hertzlia.
Dr. Hananel Elul completed his Ph.D. studies at the Faculty of Health Sciences, The Ben-Gurion University of the Negev, Beer-Sheva Israel.
His research field focuses on the biology of telomerase in the process of spermatogenesis and the effects of the AGS compounds on male fertility. Dr. Elul acquired extensive experience in Molecular Biology methods and techniques using cell cultures and animal models .
Prof. Gal Ifergane is a clinical Neurologist, active researcher, health-care executive, and consultant to pharma and biomed startup companies.
He completed his education and training in BGU and Soroka Medical Center in Beer-Sheva, Israel. Since 2012 he has served as the Head of Soroka’s Neurology department. As a Deputy Director of the medical center, Prof. Ifergane created the vision for and led the development of the Brain Medicine Division, which he also currently chairs.
Prof. Ifergane research activity focused on clinical, epidemiological and basic neuroscience in the field of headache, stroke, PTSD and other aspects of clinical neurology. He initiated and participated in several innovation initiatives, focused on the deployment of various digital and biomed technologies in various settings.
Since the beginning of the COVID-19 pandemic he extensively practiced, advocated and developed deployment programs for enhancing availability of medical care during using modern digital channels.
Prof. David Stepensky is an Associate Professor at the Department of Clinical Biochemistry and Pharmacology, Ben-Gurion University of the Negev, Beer-Sheva, Israel. He holds PhD degree from the Dept. of Pharmaceutics, School of Pharmacy, The Hebrew University of Jerusalem, Israel, and received post-doctoral training at the Dept. of Immunology, Weizmann Institute of Sciences, Rehovot, Israel and at the Dept. of Immunobiology, Yale University, New Haven, CT, USA.
His primary research interests are analysis of pharmacokinetic and pharmacodynamic properties of pharmacological agents (small molecular weight drugs and biopharmaceuticals) and development of nanovesicle- and nanoparticle-based systems that can efficiently deliver these agents to their site of action.
He authors over 50 papers and book chapters, serves as consultant to the Israeli Ministry of Health, pharmaceutical and start-up companies, and delivers customized workshops and courses on drug development, pharmaceutics, pharmacology and other topics of his research expertise.
Mr. Iftach Seri held various positions in the pharmaceutical field in Israeli and international companies for 28 years. In his last position, he served as the Chief executive officer (CEO) of wavelength Pharmaceuticals, a former subsidiary of Perrigo, and currently serves as CEO of CTS, a private Israeli pharmaceutical company operating in Israel since 1921
In the past, Seri served as Senior Vice President at the Indian company Sun, CEO of New Pharm and CEO of Pharma at Teva Israel. He was also a partner in start-ups in the fields of pharmaceuticals and food and advised companies in the field